Unexpectedly, proteins known to be involved in pathways targeted by routinely used myeloma drugs like CRBN, IKZF1, proteasome subunits, or the glucocorticoid receptor were not found deregulated at relapse. The gene discussed is CRBN; the disease is plasma cell myeloma.